Durability of first line antiretroviral therapy: reasons and predictive factors for modifications in a Swaziland cohort
OUTPUT TYPE: Journal Article
PUBLICATION YEAR: 2012
TITLE AUTHOR(S): S.Takuva, G.Louwagie, K.Zuma, V.Okello
KEYWORDS: ANTIRETROVIRAL THERAPY (ART), HIV/AIDS, SWAZILAND
DEPARTMENT: Public Health, Societies and Belonging (HSC)
Print: HSRC Library: shelf number 7114
HANDLE: 20.500.11910/3516
URI: http://hdl.handle.net/20.500.11910/3516
If you would like to obtain a copy of this Research Output, please contact Hanlie Baudin at researchoutputs@hsrc.ac.za.
Abstract
Background: Optimizing initial antiretroviral therapy (ART) regimens is critical in improving the durability of treatment efficacy and patient prognosis. Reasons for and risk factors relating to the need for ART modifications were evaluated in an outpatient cohort in Mbabane, Swaziland. Methods: We examined routine clinical data for 782 patients initiating first-line ART between 1 March 2006 and 31 March 2008. Treatment modification was defined as either a first time single drug substitution or first time regimen switch. Multivariate piecewise Cox regression models were used to identify risk factors for ART modification. Results: Over a median follow-up period of 21 months, 17.5% of patients modified their regimen. Drug toxicity (incidence rate of 6.3 per 100 person years (95% CI 5.2-7.7)) accounted for 76.6% of the reasons for modification. Drug contra-indications (incidence rate 9.5 per 100 person years (95% CI 6.5-13.9)), namely tuberculosis (13.1%) and pregnancy (6.6%), accounted for 19.7% of modifications. In the adjusted multivariate Cox piecewise regression model, beyond 11 months on ART, a baseline CD4 cell count <200 cells/mm3 (HR 4.42; 95% CI: 1.62 -12.1), having stavudine (d4T) in the initial regimen (HR 2.64; 95% CI: 1.56- 4.46), baseline weight > 60kg (HR 2.40; 95% CI: 1.43-4.04) and increase in age (HR 1.03; 95% CI: 1.00- 1.05) increased the risk of modification. Conclusions: Initiating ART earlier, at higher CD4 counts, avoiding drugs with poor safety profiles, such as d4T, and identifying individuals who may require tuberculosis treatment or may become pregnant could reduce modification rates. This would improve regimen tolerability, while preserving future treatment options.-
Related Research Outputs:
- Impact of HIV/AIDS on SADC countries: recommendations to funders
- Southern Africa: a review of the region
- A study to determine the links between HIV/AIDS, current demographic status and livelihoods in rural Swaziland
- An audit of HIV/AIDS policies in Botswana, Lesotho, Mozambique, South Africa, Swaziland and Zimbabwe
- National emergency response council on HIV/AIDS, Mbabane, Swaziland
- An exploratory study of the impact of primary caregiver HIV infection on caregiving and child developmental outcome in the era of Haart: piloting the methodology
- Universal HIV testing of infants at immunization clinics: an acceptable and feasible approach for early infant diagnosis in high HIV prevalence settings
- Use of traditional complementary and alternative medicine for HIV patients in KwaZulu-Natal, South Africa
- The phenomenology of bodily care: caregivers' experiences with AIDS patients before antiretroviral therapies in Lesotho
- Traditional complementary and alternative medicine and antiretroviral treatment adherence among HIV patients in KwaZulu-Natal, South Africa
- Rifampin pharmacokinetics in children, with and without human immunodefiency virus infection, hospitalized for the management of severe forms of tuberculosis
- Utilisation of the national antiretroviral therapy guidelines among health care professionals working in Abuja treatment centres, Nigeria
- Antiretroviral treatment adherence among HIV patients in KwaZulu-Natal, South Africa
- Traditional complementary and alternative medicine and antiretroviral treatment adherence among HIV patients in KwaZulu-Natal, South Africa
- Determinants of adherence to a single-dose nevirapine regimen for the Prevention of Mother-to-Child HIV Transmission in Gert Sibande district in South Africa
- Four-country report on formative research into the development of a HIV behavioural risk reduction intervention for PLWHA: Botswana, Lesotho, South Africa and Swaziland
- Safer sexual behaviours after 1 year of antiretroviral treatment in KwaZulu-Natal, South Africa: a prospective cohort study
- The who & why of antiretroviral treatment adherence
- A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008
- Perceived stigma among patients receiving antiretroviral therapy: a prospective study in KwaZulu-Natal, South Africa